Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing ...

Business - MarketWatch - 8 hours ago

Chancellor and BoE governor call for UK to rebuild ties with EU

Reeves and Bailey highlight damage from Brexit amid concern about Trump’s plan to impose tariffs on trading partners

Business - Financial Times - 3 hours ago

Britain’s bold plan to create super funds

The case for consolidating the UK’s sprawling pension arsenal is strong

Business - Financial Times - 9 hours ago

Biogen’s stock hit by soft sales of Alzheimer’s treatment

“We continue to see momentum with ongoing product launches and we are increasingly excited about the potential of our pipeline,” the company’s CEO said.

Business - MarketWatch - October 30

Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains traction

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company's multiple sclerosis products.

Business - CNBC - October 30

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost ...

Health - ABC News - October 23

UK regulator approves second Alzheimer's drug in months but government won't pay for it

Britain’s drug regulator approved the Alzheimer’s drug Kisunla on Wednesday, but the government won’t be paying for it after an independent watchdog agency said the treatment isn’t worth the cost ...

World - ABC News - October 23

Boeing’s stock reverses lower after announcing a $19 billion capital raise

.Boeing’s stock knee-jerked higher after a larger-than-expected capital raise was announced, but then quickly resumed its decline.

Business - MarketWatch - October 28

NHS will not fund new drug to slow Alzheimer’s

A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the watchdog says.

Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial

The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has been on a tear this year, gaining 270% to date in 2024.

Business - MarketWatch - November 4

German stocks, bond yields rise after ruling coalition collapses

Investors hope a snap election might deliver a new government that could revive Europe’s biggest economy.

Business - MarketWatch - November 7

Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase manufacturing capacity.

Business - CNBC - October 30

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of a new schizophrenia drug.

Business - MarketWatch - 3 days ago

Amgen says no concerns around weight loss drug’s bone density data after stock falls

Analysts chewed over early data showing the highest dose of Amgen's MariTide was linked to roughly 4% loss of bone mineral density over 12 weeks.

Business - CNBC - Yesterday

Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says

The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.

Business - CNBC - October 24

European committee takes a second look at Alzheimer's drug and now says it should be approved

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug

Health - ABC News - 7 hours ago

Moldova leader decries vote meddling after slim majority backs joining the E.U.

A slim majority of 50.39% voted “yes” in Moldova’s crunch referendum on European Union accession, preliminary results showed, after President Maia Sandu said that Sunday’s twin votes had been ...

The E.U. is imposing duties on electric vehicles from China after trade talks fail

The European Union is imposing duties on imports of electric vehicles from China starting Wednesday after talks between Brussels and Beijing failed.

Intuitive Surgical’s stock rises after third-quarter results beat on jump in robotic surgeries

Shares of Intuitive Surgical Inc. jumped after hours on Thursday after the company reported third-quarter results that beat Wall Street’s expectations, helped by wider adoption of its ...

Business - MarketWatch - October 17

Oil prices drop over 6% after Israeli airstrikes spare Iran’s oil facilities

Oil futures fell sharply Monday, with U.S. and global benchmark crude posting the largest one-day percentage decline in over two years after widely anticipated Israeli airstrikes against Iran did ...

Business - MarketWatch - October 28

Charter’s broadband saga may have bottomed. Has its stock done the same?

Charter shed 110,000 internet customers in the quarter, but a MoffettNathanson analyst thinks the rate of decline has bottomed out.

Business - MarketWatch - November 1

Home Depot earnings sweep past estimates, but interest rates pressure home remodeling

Home Depot executives discussed the impact of President-elect Donald Trump’s proposal to impose new tariffs.

Business - MarketWatch - 2 days ago

Bullying and harassment claims rise across City, regulator finds

Increase in reports of incidents could point to better culture rather than worse conditions, FCA says

Business - Financial Times - October 24

Banks and regulators warn of rise in ‘quishing’ QR code scams

HSBC, Santander and the US Federal Trade Commission concerned over email attacks that bypass cyber-defences

Business - Financial Times - October 27

Pandora Narrows Sales View as Revenue Rises

The Danish jeweler now sees 2024 sales coming in toward the high end of its previous forecast despite a sluggish environment for luxury goods.

Business - The Wall Street Journal - November 6

Bank stocks jump almost 12% as traders bet on less regulation in a Trump presidency

A handful of well-known bank names jumped as traders ready for a second Trump term.

Business - CNBC - November 6

Robert F. Kennedy Jr., Foe of Drug Makers and Regulators, Is Poised to Wield New Power

President-elect Donald Trump has encouraged him to “go wild on health” but has not made clear what role Mr. Kennedy will play.

Health - The New York Times - November 6

‘Drugs were everywhere’: the rise and fall of the NBA’s cocaine era

Recreational drug use boomed in the 1980s and basketball was far from immune. The trend ended careers as the NBA clamped down. Micheal Ray Richardson was a brilliant player: a four-time NBA ...

World - The Guardian - October 23

Ozempic, Wegovy popularity leads to rise of fake weight loss drugs

The demand for weight loss drugs like Ozempic and Wegovy has led to a flood of fake drugs hitting the market. However, these counterfeit medicines can be harmful to people's health. Tom Hanson has ...

US shares and Bitcoin hit record highs on Trump win

The result could have a far-reaching implications for tax and trade policy, as well as economies around the world.

University cash crisis to get worse despite tuition fee rise, regulator says

More than three quarters of universities are expected to face financial problems next year.

Pair sentenced for drug supply after teenager died

Lucy Hill, 16, died in December 2022 after taking MDMA and collapsing at a nightclub.

AbbVie shares tumble after schizophrenia drug disappoints

US pharma group says patients who took Emraclidine in clinical trials failed to show a significant decline in symptoms

Business - Financial Times - 3 days ago

'Shaken baby syndrome' execution on hold after Texas Supreme Court decision

Robert Roberson was sentenced to death based on the largely discredited "shaken baby syndrome" hypothesis.

Latest in Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug